scholarly journals Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand

PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0255796
Author(s):  
Sarunporn Tandhavanant ◽  
Sirikamon Koosakunirand ◽  
Taniya Kaewarpai ◽  
Watcharapong Piyaphanee ◽  
Pornsawan Leaungwutiwong ◽  
...  
Keyword(s):  
Serum Sample ◽  
Receptor Binding ◽  
Binding Protein ◽  
Natural Infection ◽  
Igg Subclasses ◽  
Antibody Responses ◽  
Healthy Individuals ◽  
Serum Samples ◽  
Recombinant Receptor ◽  
Receptor Binding Protein

Serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might contribute to confirming the suspected coronavirus disease 2019 (COVID-19) in patients not detected with molecular assays. Human antibodies that target the host angiotensin-converting enzyme 2-binding domain of the viral spike protein are a target for serodiagnosis and therapeutics. This study aimed to characterize the classes and subclasses of antibody responses to a recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients and investigated the reactivity of these antibodies in patients with other tropical infections and healthy individuals in Thailand. ELISAs for IgM, IgA, IgG and IgG subclasses based on RBD antigen were developed and tested with time series of 27 serum samples from 15 patients with COVID-19 and 60 samples from pre-COVID-19 outbreaks including acute dengue fever, murine typhus, influenza, leptospirosis and healthy individuals. Both RBD-specific IgA and IgG were detected in only 21% of the COVID-19 patients in the acute phase. The median IgA and IgG levels were significantly higher in the convalescent serum sample compared to the acute serum sample (P < 0.05). We observed the highest correlation between levels of IgG and IgA (rho = 0. 92). IgG1 and IgG3 were the major IgG subclasses detected in SARS-CoV-2 infection. Only acute IgG3 level was negatively associated with viral detection based on RT-PCR of ORF1ab gene (rho = -0.57). The median IgA and IgG levels in convalescence sera of COVID-19 patients were significantly higher than healthy individuals and convalescent sera of other febrile infectious patients. The analyses of antibody classes and subclasses provide insights into human immune responses against SARS-CoV-2 during natural infection and interpretation of antibody assays.

scholarly journals F1Aα, a Death Receptor-binding Protein Homologous to theCaenorhabditis elegansSex-determining Protein, FEM-1, Is a Caspase Substrate That Mediates Apoptosis

1999 ◽  
Vol 274 (45) ◽  
pp. 32461-32468 ◽  
Author(s):  
Shing-Leng Chan ◽  
Kuan-Onn Tan ◽  
Li Zhang ◽  
Karen S. Y. Yee ◽  
Francesca Ronca ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Binding Protein ◽  
Death Receptor ◽  
Caspase Substrate ◽  
Receptor Binding Protein

Specific detection of Campylobacter jejuni using the bacteriophage NCTC 12673 receptor binding protein as a probe

The Analyst ◽  
2011 ◽  
Vol 136 (22) ◽  
pp. 4780 ◽  
Author(s):  
Amit Singh ◽  
Denis Arutyunov ◽  
Mark T. McDermott ◽  
Christine M. Szymanski ◽  
Stephane Evoy
Keyword(s):  
Campylobacter Jejuni ◽  
Receptor Binding ◽  
Binding Protein ◽  
Specific Detection ◽  
Receptor Binding Protein

Receptor binding protein amperometric affinity sensor for rapid β-lactam quantification in milk

1999 ◽  
Vol 398 (1) ◽  
pp. 13-22 ◽  
Author(s):  
S.J. Setford ◽  
R.M. Van Es ◽  
Y.J. Blankwater ◽  
S. Kröger
Keyword(s):  
Receptor Binding ◽  
Binding Protein ◽  
Receptor Binding Protein

scholarly journals Correlation of the commercial anti-SARS-CoV-2 receptor binding domain antibody test with the chemiluminescent reduction neutralizing test and possible detection of antibodies to emerging variants

2021 ◽  
Author(s):  
Yoshitomo Morinaga ◽  
Hideki Tani ◽  
Yasushi Terasaki ◽  
Satoshi Nomura ◽  
Hitoshi Kawasuji ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Disease Onset ◽  
Antibody Test ◽  
Binding Domain ◽  
Receptor Binding Domain ◽  
Healthy Individuals ◽  
Wild Type ◽  
Serum Samples ◽  
Serological Tests ◽  
Convalescent Phase

Background Serological tests are beneficial for recognizing the immune response against SARS-CoV-2. To identify protective immunity, optimization of the chemiluminescent reduction neutralizing test (CRNT), using pseudotyped SARS-CoV-2, is critical. Whether commercial antibody tests are comparably accurate is unknown. Methods Serum samples collected before variants were locally found were obtained from confirmed COVID-19 patients (n = 74), confirmed non-COVID-19 individuals (n = 179), and unscreened individuals (suspected healthy individuals, n = 229). The convalescent phase was defined as the period after day 10 from disease onset. The CRNT against pseudotyped viruses displaying the wild-type spike protein and a commercially available anti-receptor binding domain (RBD) antibody test were assayed. The CRNT was also assayed, using South African (SA) and United Kingdom (UK)-derived variants. Results The CRNT (cut off value, 50% inhibition) and the anti-RBD antibody test (cut off value, 0.8 U/mL) concurred regarding symptomatic COVID-19 patients in the convalescent phase and clearly differentiated between patients and suspected healthy individuals (sensitivity; 95.8% and 100%, specificity; 99.1% and 100%, respectively). Anti-RBD antibody test results correlated with neutralizing titer (r = 0.47, 95% CI 0.20-0.68). Compared with the wild-type, CRNT reduction was observed for the SA and UK-derived variants. Of the samples with ≥100 U/mL by the anti-RBD antibody test, 77.8% and 88.9% showed ≥50% neutralization against the UK and the SA variants, respectively. Conclusion The CRNT and commercial anti-RBD antibody test effectively classified convalescent COVID-19 patients. The strong positive results using the commercial antibody test can reflect neutralizing activity against emerging variants.

scholarly journals A receptor-binding protein ofCampylobacter jejunibacteriophage NCTC 12673 recognizes flagellin glycosylated with acetamidino-modified pseudaminic acid

2014 ◽  
Vol 95 (1) ◽  
pp. 101-115 ◽  
Author(s):  
Muhammad Afzal Javed ◽  
Lieke B. van Alphen ◽  
Jessica Sacher ◽  
Wen Ding ◽  
John Kelly ◽  
...  
Keyword(s):  
Receptor Binding ◽  
Binding Protein ◽  
Pseudaminic Acid ◽  
Receptor Binding Protein

scholarly journals Peroxisome-proliferator-activated receptor-binding protein (PBP) is essential for the growth of active Notch4-immortalized mammary epithelial cells by activating SOX10 expression

2009 ◽  
Vol 425 (2) ◽  
pp. 435-444 ◽  
Author(s):  
Yiwei Tony Zhu ◽  
Yuzhi Jia ◽  
Liping Hu ◽  
Chao Qi ◽  
Megana K. Prasad ◽  
...  
Keyword(s):  
Growth Inhibition ◽  
Receptor Binding ◽  
Binding Protein ◽  
Active Form ◽  
Mammary Epithelial ◽  
Peroxisome Proliferator ◽  
Mammary Cells ◽  
Peroxisome Proliferator Activated Receptor ◽  
Sox10 Expression ◽  
Receptor Binding Protein

PBP (peroxisome-proliferator-activated receptor-binding protein) [Med1 (mediator 1)/TRAP220 (thyroid-hormone-receptor-associated protein 220)] is essential for mammary gland development. We established a mammary epithelial cell line with a genotype of PBPLoxP/LoxP by expressing an active form of Notch4. Null mutation of PBP caused severe growth inhibition of the Notch4-immortalized mammary cells. We found that truncated PBP without the two LXXLL motifs could reverse the growth inhibition due to the deficiency of endogenous PBP, indicating that signalling through nuclear receptors is unlikely to be responsible for the growth inhibition as the result of PBP deficiency. Loss of PBP expression was shown to completely ablate the expression of SOX10 [Sry-related HMG (high-mobility group) box gene 10]. The re-expression of SOX10 was capable of reversing the growth inhibition due to PBP deficiency, whereas suppressed expression of SOX10 inhibited the growth of Notch4-immortalized mammary cells. Further studies revealed PBP is directly recruited to the enhancer of the SOX10 gene, indicating that SOX10 is a direct target gene of PBP. We conclude that PBP is essential for the growth of Notch4-immortalized mammary cells by activating SOX10 expression, providing a potential molecular mechanism through which PBP regulates the growth of mammary stem/progenitor cells.

scholarly journals Regulation of synaptic structure and function by palmitoylated AMPA receptor binding protein

2010 ◽  
Vol 43 (4) ◽  
pp. 341-352 ◽  
Author(s):  
Charu Misra ◽  
Sophie Restituito ◽  
Jainne Ferreira ◽  
Gerald A. Rameau ◽  
Jie Fu ◽  
...  
Keyword(s):  
Ampa Receptor ◽  
Receptor Binding ◽  
Binding Protein ◽  
Structure And Function ◽  
Synaptic Structure ◽  
Ampa Receptor Binding Protein ◽  
And Function ◽  
Receptor Binding Protein
Sign in / Sign up

Export Citation Format

Share Document